CAMBRIDGE, MA / ACCESS Newswire / July 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...

Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by ...

Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

The Department of Health and Human Services plans to cancel contracts and pull funding for some vaccines being developed to ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

HHS announced that it will no longer fund internal department research for mRNA vaccines for upper respiratory viruses like flu and COVID-19.

Moderna Inc. (NASDAQ: MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year ...